Peptide Therapy for Veterans: New Bill Would Direct VA Study

A new House bill would direct the Department of Veterans Affairs to formally study peptide-based therapies for veterans — a step that would bring the compounds most popular in the wellness and recovery market into the evaluation pipeline of the largest integrated health system in the United States.

Representative Nancy Mace (R-S.C.) introduced the legislation on September 1 as the Providing Evidence-based Peptide Therapies to Improve Delivery and Expanded Services for Veterans Act — the “PEPTIDES for Veterans Act”. The bill was designated H.R. 10212 and referred to the House Committee on Veterans’ Affairs the same day, according to the official congressional record.

“Our veterans sacrificed everything to protect our country. The least we can do is make sure they have access to groundbreaking treatments,” Mace said in a press release. “The VA shouldn’t bury promising advancements in bureaucracy simply because they’re new. Study it. Test it. Follow the evidence.”

What the PEPTIDES for Veterans Act Would Do

The bill is structured as a study-and-pilot measure rather than an access mandate. It would require the VA Secretary to take three sequential steps:

• A regulatory review. Within 180 days of enactment, the VA Secretary would conduct a comprehensive review of existing regulations and guidance surrounding peptides and submit a report to Congress.
• An 18-month study. Following the review, the VA would study peptide-based therapies as potential treatments for recovery, rehabilitation, chronic pain, mental health, physical wellness, and other service-connected conditions.
• A conditional pilot. If the study determines peptide-based therapies are safe and beneficial, the legislation directs the VA to launch a pilot program for veterans who voluntarily elect to participate, evaluating real-world outcomes and assessing the potential for large-scale implementation across VA medical facilities.

“The VA bureaucracy has stood between veterans and the care they earned for too long,” Mace added. “If peptide therapies can help veterans manage pain, recover faster, or improve their mental and physical health, they deserve the treatment.”

Why the Bill Arrives Now

The legislation lands at a moment when the federal regulatory status of peptides is in flux. In April, the FDA removed 12 peptides from its Category 2 “do not compound” list, and in July its Pharmacy Compounding Advisory Committee voted to recommend six of them — including BPC-157 — for the 503A bulks list, a decision PeptidesBeat covered in detail. None of those peptides is an FDA-approved drug, and the agency’s final bulks-list rulemaking is still pending.

That regulatory gray zone is precisely what the bill’s first step targets. By requiring a review of “existing regulations and guidance surrounding peptides,” the legislation would force the VA to map what formal position — if any — the department has taken on compounds that are widely available through private clinics and, in some states, compounding pharmacies.

The choice of conditions is notable: chronic pain, recovery, and mental health are the uses most commonly associated with recovery-market peptides such as BPC-157, which have attracted attention from athletes and service members but lack the large controlled trials needed for FDA approval.

What the Bill Does Not Do

The bill would not, by itself, change the FDA status of any peptide, add a peptide to VA formularies, or direct the VA to prescribe or dispense anything. It contains no funding authorization for peptide procurement and no requirement that any veteran participate — the pilot, if it materializes, would be limited to voluntary participants after a favorable study finding.

In that respect the legislation is a study-authorization bill: it asks for evidence before access, and the evidence-gathering alone would stretch past the current session of the 119th Congress, which ends in January 2027.

What Happens Next

H.R. 10212 now sits with the House Committee on Veterans’ Affairs. No hearing has been scheduled. Veterans’ health legislation of this type typically needs committee markup and floor time in both chambers before the end of the Congress — a compressed window given the bill was introduced in September of an election-year session.

The bill’s progress is worth watching for a reason beyond the VA itself: a federal health system formally evaluating peptide therapies would mark a significant institutional shift for compounds that have spent most of 2026 moving from the gray market to the regulatory agenda.

PeptidesBeat is an independent editorial publication covering peptide policy, research, and industry developments. We do not sell peptides, recommend dosing, or provide medical advice. All content is informational. Peptides referenced may be subject to FDA restrictions; consult a licensed healthcare provider for any therapeutic question.